Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CTSK | P43235 | 9/20 | 0.40 |
| ▸ | CTSS | P25774 | 4/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 2/20 | 0.36 |
| ▸ | CTSB | P07858 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16885227 | 0.80 | CYP2D6 (0.69) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL16885212 | 0.80 | CYP2D6 (0.69) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL20040036 | 0.79 | CA1 (0.51) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL15692648 | 0.79 | CA1 (0.51) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL20557220 | 0.79 | CA1 (0.49) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL7353657 | 0.79 | CA1 (0.49) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL7360111 | 0.79 | CA1 (0.49) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL7205694 | 0.79 | CA1 (0.46) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL10535046 | 0.78 | CYP2D6 (0.77) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL10535960 | 0.78 | CYP2D6 (0.77) | CYP2D6CA1CA2CA7CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2681187-B1 | PROCESS FOR REDUCTION OF ALPHA-ACYLOXY SULFIDE DERIVATIVES | SCINOPHARM TAIWAN LTD (TW) | 2018-04-11 | — | — | EP | disclosed |
| US-8722921-B2 | Process for reduction of alpha-acyloxy sulfide derivatives | SCINOPHARM SINGAPORE PTE, LTD. (SG) | 2014-05-13 | — | — | US | disclosed |
| US-20120220784-A1 | PROCESS FOR REDUCTION OF ALPHA-ACYLOXY SULFIDE DERIVATIVES | SCINOPHARM SINGAPORE PTE, LTD. (SG) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220784-A1 | PROCESS FOR REDUCTION OF ALPHA-ACYLOXY SULFIDE DERIVATIVES | SULT1A1, SQOR, SULT2A1 | CYP2D6 288/4885CA1 2242/4885CA2 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.